Regeneron Pharmaceuticals
REGN
553 hedge funds and large institutions have $29.4B invested in Regeneron Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 182 increasing their positions, 219 reducing their positions, and 45 closing their positions.
38% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 45
16% more capital invested
Capital invested by funds: $25.3B → $29.4B (+$4.1B)
2% more funds holding
Funds holding: 541 → 553 (+12)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
17% less repeat investments, than reductions
Existing positions increased: 182 | Existing positions reduced: 219
23% less call options, than puts
Call options by funds: $630M | Put options by funds: $822M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$461M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$265M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$194M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$88.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$78.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$248M |
| 2 |
JP Morgan Chase
New York
|
-$161M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$113M |
| 4 |
Two Sigma Investments
New York
|
-$103M |
| 5 |
Renaissance Technologies
New York
|
-$73.6M |
REGN Hedge Fund Activity: Q3 2016 in Review
553 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2016, worth a combined $29.4B — up 16% from $25.3B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new REGN positions and 45 closed out — a net gain of 17 holders — while 182 added to existing stakes and 219 trimmed.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $461M. The largest seller was T. Rowe Price Associates, cutting an estimated $248M.
- 553 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2016, up from 541 in Q2 2016.
- Funds reported $29.4B of Regeneron Pharmaceuticals stock for Q3 2016, up 16% quarter-over-quarter.
- 62 funds opened new Regeneron Pharmaceuticals positions in Q3 2016 and 45 closed out, a net change of +17 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2016 was Loomis, Sayles & Company, an estimated $461M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2016 was T. Rowe Price Associates, an estimated $248M sold.
Based on aggregated 13F filings for Q3 2016.